Current management of primary central nervous system lymphoma.
Publication/Presentation Date
8-1-2017
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare but treatable disease. The hallmark therapy is based on the use of high-dose intravenous methotrexate (HDMTX), with clinical trial data suggesting that a more aggressive and targeted chemoimmunotherapeutic approach, to include the use of targeted therapy with rituximab (RTX) and the addition of other chemotherapeutic agents, may improve prognosis and reduce or defer the need for radiation therapy. Understanding of the molecular basis of tumor growth and proliferation may allow for the use of new targeted agents.
Volume
6
Issue
4
First Page
38
Last Page
38
ISSN
2304-3873
Published In/Presented At
Glass J. (2017). Current management of primary central nervous system lymphoma. Chinese clinical oncology, 6(4), 38. https://doi.org/10.21037/cco.2017.06.24
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
28841800
Department(s)
Administration and Leadership
Document Type
Article